Current management of necrotizing soft-tissue infections

Link to article at PubMed

Curr Opin Infect Dis. 2021 Apr 1;34(2):89-95. doi: 10.1097/QCO.0000000000000700.


PURPOSE OF REVIEW: The aim of the article is to present recent epidemiological, microbiological, and clinical data for the surgical, antimicrobial, and adjunctive management of necrotizing soft-tissue infections (NSTI).

RECENT FINDINGS: NSTI can be caused by a broad variety of organisms. Reports about NSTI caused by multidrug-resistant bacteria are increasing. Owing to the rareness of NSTI, general clinical awareness is low and prompt diagnosis is often delayed. New diagnostic instruments (scoring systems, MRI) have either a low accuracy or are time consuming and cannot guide clinicians reliable currently. The value of adjunctive measures (intravenous immunoglobulin, hyperbaric oxygen therapy) is uncertain as well. Morbidity and mortality in NSTI remain high, ranging from 20 up to over 30%.

SUMMARY: Early radical surgical debridement and empirical broad-spectrum antimicrobial treatment remain the cornerstones of therapy in NSTI. Further clinical research is necessary to shorten diagnostic pathways and to optimize surgical, antimicrobial, and adjunctive treatment.

PMID:33278180 | DOI:10.1097/QCO.0000000000000700

Leave a Reply

Your email address will not be published.